Prevalence and risk factors for XXXX associated with parenteral @entity6414 use.

@entity1 @entity8 @entity6414 @entity1483 @entity177 @entity810 @entity1011
BACKGROUND: The main adverse effect of @entity6414 is nephrotoxicity. There are few data on polymyxin-associated @entity8 . OBJECTIVE: To assess the prevalence of and risk factors for @entity810 ( @entity810 ) in @entity1 treated with @entity6414 . METHODS: The studied population included 114 @entity1 who received at least 3 consecutive days of intravenous @entity6414 and had baseline serum @entity1011 (SCr) and at least one further SCr measurement during treatment. @entity810 was defined as an SCr increase to 1.8 mg/dL or greater in @entity1 with baseline SCr less than 1.5 mg/dL, or an increase greater than or equal to 50% in baseline SCr when it was already greater than or equal to 1.5 mg/dL, or need for dialysis. RESULTS: @entity810 developed in 22% of the @entity1 . They were older, had a higher baseline SCr, had a higher frequency of baseline SCr greater than or equal to 1.5 mg/dL, used other nephrotoxic drugs and @entity1483 more often, and required vasoactive drugs and mechanical ventilation more frequently. Progression to @entity177 was significantly more probable when the bacteria were isolated in the abdomen, catheter, or blood. @entity810 @entity1 had a higher mortality rate (92% vs 53%; p < 0.001). Logistic regression identified abnormal baseline SCr (odds ratio [OR] 3.51); need for vasoactive drugs (OR 3.03); and abdomen, blood, or catheter as the infection site (OR 3.82) as independent risk factors for @entity810 . CONCLUSIONS: @entity1 who developed @entity810 had a strikingly elevated mortality rate. @entity6414 should be used with extreme caution in @entity1 who have an abnormal baseline SCr; use vasoactive drugs; or have abdomen, blood, or catheter as the infection site.
